Regeneron Pharmaceuticals, Inc. $REGN Stock Sold by Lockheed Martin Investment Management Co.

Lockheed Martin Investment Management Co. reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,210 shares of the biopharmaceutical company’s stock after selling 990 shares during the period. Lockheed Martin Investment Management Co.’s holdings in Regeneron Pharmaceuticals were worth $1,676,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $5,682,636,000. Legal & General Group Plc purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at about $473,872,000. Bank of New York Mellon Corp purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at about $472,950,000. Deutsche Bank AG acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at about $323,249,000. Finally, Man Group plc acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at about $272,460,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the sale, the executive vice president owned 13,134 shares in the company, valued at approximately $11,163,900. This represents a 8.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joseph J. Larosa sold 4,466 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the sale, the executive vice president directly owned 38,906 shares in the company, valued at $37,563,353.94. The trade was a 10.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 27,028 shares of company stock valued at $25,025,950 in the last 90 days. 6.97% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on REGN. Royal Bank Of Canada raised their price objective on Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the stock a “sector perform” rating in a research note on Monday, November 2nd. Jefferies Financial Group upped their target price on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Robert W. Baird raised their price target on shares of Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the stock a “neutral” rating in a research report on Monday, November 2nd. Finally, Raymond James Financial lifted their price objective on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $898.97.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $919.96 on Tuesday. The stock has a 50-day simple moving average of $806.90 and a two-hundred day simple moving average of $743.66. The firm has a market capitalization of $94.72 billion, a P/E ratio of 20.31, a PEG ratio of 1.38 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 3.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same quarter in the previous year, the firm posted $11.83 EPS. The company’s revenue for the quarter was up 36.3% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.